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Rachel M. Maison8, Anna Gazumyan3, David R. Martinez1, Ralph S. Baric1,5, Davide F. Robbiani3,6, Theodora Hatziioannou2,
Jeffrey V. Ravetch4, Paul D. Bieniasz2,7, Richard A. Bowen8, Michel C. Nussenzweig3,7, and Timothy P. Sheahan1
SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million infections and 1 million deaths since its
emergence in December 2019. There are few therapeutic options and no approved vaccines. Here, we examine the properties of
highly potent human monoclonal antibodies (hu-mAbs) in a Syrian hamster model of SARS-CoV-2 and in a mouse-adapted
model of SARS-CoV-2 infection (SARS-CoV-2 MA). Antibody combinations were effective for prevention and in therapy when
administered early. However, in vitro antibody neutralization potency did not uniformly correlate with in vivo protection, and
some hu-mAbs were more protective in combination in vivo. Analysis of antibody Fc regions revealed that binding to
activating Fc receptors contributes to optimal protection against SARS-CoV-2 MA. The data indicate that intact effector
function can affect hu-mAb protective activity and that in vivo testing is required to establish optimal hu-mAb combinations for
COVID-19 prevention.
Introduction
Coronaviruses (CoVs) have a penchant for host range expansion,
jumping from reservoir species to different hosts, resulting in
newly emerging human infectious diseases. Indeed, in the last
20 yr, three novel human CoVs have emerged, causing epidemic
and pandemic diseases most recently exemplified by SARS-CoV-2,
the causative agent of COVID-19 (de Wit et al., 2016; Zhou et al.,
2020).
Effective therapeutics are desperately needed to address the
COVID-19 pandemic, as there is currently only one Food and
Drug Administration–approved therapy (remdesivir) and one
treatment authorized for emergency use (convalescent plasma;
U.S. Food and Drug Administration, 2020). Human mAbs (hu-
mAbs) hold great potential for treatment and prevention of
COVID-19, and several potent SARS-CoV-2–specific mAbs tar-
getingmultiple nonoverlapping epitopes in the receptor-binding
domain (RBD) in the spike (S) protein have been reported
(Robbiani et al., 2020; Baum et al., 2020; Cao et al., 2020; Hansen
et al., 2020; Ju et al., 2020; Liu et al., 2020; Pinto et al., 2020;
Wang et al., 2020 Preprint; Zost et al., 2020a; Li et al., 2020).
Some of these hu-mAbs have been tested for their ability to
prevent or treat SARS–CoV-2 infection in rhesus macaques and
hamsters with variable but encouraging results (Rogers et al.,
2020; Liu et al., 2020; Shi et al., 2020; Hansen et al., 2020).
However, the role of antibody effector function, relative neu-
tralization potency, and combinations in protection have not
been examined to date in part because performing experiments
in macaques under BSL3 conditions is challenging. In addition to
the traditional antibody Fc-effector functions (i.e., antibody-
dependent cellular cytotoxicity, phagocytosis, etc.), Fc and cel-
lular Fc-receptor interactions drive aspects of both innate and
adaptive immunity including macrophage polarization, antigen
presentation, and B cell activation. Thus, the Fc-mediated ef-
fector functions of neutralizing antibodiesmay also play a role in
shaping diverse aspects of the adaptive immune response.
Small animal models of SARS-CoV-2 replication and patho-
genesis are essential for the preclinical development of vaccines
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and therapeutics. However, SARS-CoV-2 cannot infect standard
laboratory mice due to incompatibility between the RBD and
the murine orthologue of the human viral entry receptor,
angiotensin-converting enzyme receptor-2 (mACE2; Zhou et al.,
2020; Walls et al., 2020; Letko et al., 2020). To obviate this
problem, we developed an immune-competent mouse model of
COVID-19 by remodeling the SARS-CoV-2 S RBD at the mACE2-
binding interface (Dinnon et al., 2020). The recombinant virus,
mouse-adapted SARS-CoV-2 (SARS-CoV-2 MA), replicates to
high titers in the lungs of laboratory mice and has been used to
evaluate COVID-19 vaccines and therapeutics including hu-
mAbs (Dinnon et al., 2020; Zost et al., 2020a; Corbett et al.,
2020). Here, we examine the role of antibody potency, effec-
tor function, and antibody combinations on protection from
SARS-CoV-2 MA infection in mice and SARS-CoV-2 infection in
Syrian hamsters in vivo.
Results
The effect of mouse adapting spike mutations on antibody
neutralization in vitro
To determine if the two amino acid changes (Q498T/P499Y) in
the mouse-adapted SARS-CoV-2 S RBD would affect antibody
neutralization, we used HIV-1 virus pseudotyped with the SARS-
CoV-2-MA S protein (S-MA). The recombinant pseudovirus
was produced by cotransfection of S-MA with a replication-
incompetent proviral genome (NL4-3ΔEnv-NanoLuc) that lacks
a functional env gene and encodes a nanoluciferase reporter in
the place of the nef gene (Fig. 1 A; Robbiani et al., 2020; Schmidt
et al., 2020). To maximize S-incorporation, we truncated the
C-terminus of S-MA by 19 amino acids. Using nanoluciferase
reporter expression as a measure of infection, we compared the
ability of pseudotyped virus bearing either WT SARS-CoV-2 S
(wtS) or S-MA to infect HT1080 cells stably expressing either
human or murine ACE2. Consistent with previous reports (Zhou
et al., 2020; Dinnon et al., 2020), wtS did not support pseudo-
virus infection of murine ACE2–expressing cells (Fig. 1 B), as
relative light units (RLUs) remain at background levels observed
with viruses lacking spike (Fig. 1 B). In contrast, the SARS-CoV-
2 MA supported robust infection of both mouse and human
ACE2–expressing cells (Fig. 1 B).
The S-MA pseudotyped virus was used to measure the neu-
tralizing activity of eight different IgG1 hu-mAbs with variable
potencies against SARS-CoV-2 ranging from inhibitory concen-
tration (IC)50/IC90 (half-maximal/90% IC) of 4.4/18 to 26/
140 ng/ml (Table 1; Robbiani et al., 2020). C002, C104, C105,
C119, C121, and C144 all target the hACE2 interaction surface of
the RBD albeit at different angles of approach, and C135 and C110
target a separate nonoverlapping epitope within the RBD
(Robbiani et al., 2020; Barnes et al., 2020b). With the exception
of C119, the antibody neutralization titers were similar when
assayed using S-MA or wtS pseudotyped viruses (R = 0.81, P =
0.02; Table 1 and Fig. 1 C and D). C119 was inactive against S-MA
pseudotyped virus because the epitope targeted by this antibody
overlaps the mouse-adapting mutations (Fig. 1 C; Dinnon et al.,
2020; Barnes et al., 2020a Preprint). Overall, however, mouse-
adapting mutations in the S protein do not significantly affect
neutralization by most RBD-targeting antibodies tested in vitro.
In vitro antibody neutralization does not uniformly correlate
with its in vivo efficacy
To determine if there is a correlation between in vitro neutral-
ization and in vivo activity, we performed prophylactic efficacy
studies in aged BALB/c mice infected with SARS-CoV-2 MA.
mAbs (8 mg/kg) were administered by intraperitoneal injection
12 h before intranasal infection with 105 PFU of SARS-CoV-2 MA
(Fig. 2 A). Viral lung titers were measured by plaque assay 2 d
after infection, which is the kinetic peak of viral replication in
Figure 1. Antibody potency against the SARS-CoV-2 MA
spike. (A) Diagram of the MA SARS-CoV-2 pseudovirus lu-
ciferase assay. SARS-CoV-2 S-MA pseudotyped HIV-1 par-
ticles carrying the nanoluc gene are used to infect
muAce2-expressing HT1080 cells, which will express
nanoluc luciferase upon infection, while wtS pseudotyped
particles are unable to infect muAce2-expressing cells. Yel-
low stars indicate visible light released by the nanoluciferase
(nLUC) reaction. (B) RLU reads from lysates of muAce2 and
human (hu) Ace2–expressing HT1080 cells infected with
increasing amounts of SARS-CoV-2 S-MA and wtS pseudo-
virus, as well as nonpseudotyped control virus (w/o S). Data
are mean ± standard deviation of triplicates. One represen-
tative experiment is shown. nluc, nanoluc. (C) % neutrali-
zation measured for cell lysates of HT1080muAce2 cells 48 h
after infection with SARS-CoV-2 S-MA pseudovirus in the
presence of increasing concentrations of mAbs. n = 8 sam-
ples and 1 isotype control. Data points are shown as circles
and curve fits as lines. Data are mean of duplicates, and one
representative experiment is shown. ctr, control. (D) IC90
values detected in the SARS-CoV-2 S-MA pseudovirus neu-
tralization assay (IC90-murine) plotted against those de-
tected in the wtS SARS-CoV-2 pseudovirus neutralization
assay (IC90-human). R2 = 0.8095; P < 0.02178. Mean values
of at least two experiments are shown. ns, not significant.
Schäfer et al. Journal of Experimental Medicine 2 of 9
In vivo efficacy of anti–SARS-CoV-2 antibodies https://doi.org/10.1084/jem.20201993
this model (Dinnon et al., 2020). Since this is primarily a virus
replication model, infected mice did not display overt disease.
Mice injected with the isotype control antibody (anti-Zika an-
tibody 3633; Robbiani et al., 2017) had mean viral lung titers of
106 PFU (Fig. 2 A and Table 2). In agreement with the in vitro
neutralization data, C119 failed to protect against SARS-CoV-2
MA in vivo (Fig. 1 C, Fig. 2 A, and Table 2). In contrast, the other
anti–SARS-CoV-2 antibodies tested protected against infection
to varying degrees (Fig. 2 A). C104 (IC90 223 ng/ml) reduced viral
loads in the lungs of all mice to below the limit of detection
(i.e., 50 PFU). Other antibodies that were more potent than C104
against SARS-CoV-2 MA pseudoviruses in vitro lowered viral
loads by 2–4 orders of magnitude (Fig. 2 A; C002, C110, C121-LS,
C135-LS, and C144-LS). The LSmutation increases antibody half-
life but does not alter potency or effector function (Zalevsky
et al., 2010). Interestingly, C105 only reduced the viral loads
in vivo by 1–2 orders of magnitude, yet its neutralizing activity
against SARS-CoV-2 MA pseudotyped virus in vitro was similar
to that of C104 (Fig. 1, Fig. 2, and Table 1). Comparison of the
mean viral lung titer and respective IC90 revealed that the
in vitro neutralizing activity in pseudovirus assays did not
uniformly correlate with in vivo efficacy (Fig. 2 B).
Antibody Fc-effector function contributes to neutralization of
SARS-CoV-2 MA in vivo
Virus neutralization in vitro is independent of antibody Fc-
effector functions that impact in vivo efficacy against other vi-
ral infections (Lu et al., 2016; Halper-Stromberg et al., 2014;
DiLillo et al., 2014; Bournazos et al., 2019; DiLillo et al., 2016;
Bournazos et al., 2014). To examine the role of Fc-effector
function on the neutralization of SARS-CoV-2 MA in vivo, we
introduced the G236R/L328R (GRLR) mutation that abrogates
antibody Fc receptor interaction in C002, C104, and C110 (Fig. 3;
Bournazos et al., 2014). C002 and C104 target epitopes on the
ACE2-binding interface of RBD, while C110 targets RBD but does
not directly overlap the ACE2 interaction surface (Robbiani
et al., 2020; Barnes et al., 2020a Preprint). As expected, the
three antibody variants (C002GRLR, C104GRLR, and C110GRLR) had
IC90 values that were not significantly different from those of
WT hu-mAbs in SARS-CoV-2 MA pseudovirus assays in vitro
(Fig. 3, A and B). Elimination of Fc-effector function did not
significantly affect in vivo protection by C002, the least potent
of the three antibodies (Fig. 3 C and Table 3; C002 = 9.9 × 102 PFU
vs. C002GRLR = 1.6. × 103 PFU; P = 0.72). In contrast, loss of Fc-
effector function significantly decreased the potency of both
C104GRLR and C110GRLR (Fig. 3 C). Fc null C104GRLR was 14-fold
and C110GRLR sixfold less potent than their Fc effector–sufficient
counterparts (P = 0.0001 and P = 0.004, respectively; Fig. 3 C
and Table 3). Variable Fc-effector requirements were also ob-
served for anti-influenza antibodies, suggesting that the nature
Table 1. Inhibitory concentrations of mAbs
Antibody ID Murine Human
IC50 (ng/ml) IC90 (ng/ml) IC50 (ng/ml) IC90 (ng/ml)
C002 3.7 29.9 8.9a 37.6a
C002-GRLR 3.8 22.7
C104 6.8 223.9 23.3a 140.3a
C104-GRLR 15.4 160.5
C105 8.0 129.8 26.1a 133.7a
C110 22.6 176.9 18.4a 77.3a
C110-GRLR 8.1 267.5
C119 >1,000 >1,000 9.1a 97.8a
C121-LS 6.5 73.5 10.7 54.0
C135-LS 6.9 31.5 17.3 36.3
C144-LS 3.2 30.2 4.4 18.2
aRobbiani et al. (2020)
Figure 2. In vivo potency does not uniformly correlate with in vitro
potency. (A) SARS-CoV-2 MA lung titer following antibody prophylaxis.
Antibodies (8 mg/kg) were delivered intraperitoneally 12 h before infection
with 105 PFU of SARS-CoV-2 MA. Combined data from two independent
experiments are shown. All groups are n = 10 mice/group except for C119 and
C135-LS. The line is at the geometric mean, and each symbol represents the
titer for a single animal. Asterisks indicate statistical differences compared
with isotype control by Kruskal-Wallis test with a Dunn’s multiple compari-
son test (****, P < 0.0001; ***, P = 0.0003; **, P = 0.007–0.004). (B) PFU/
lobe values plotted against IC90 values detected in the SARS-CoV-2 S-MA
pseudovirus neutralization assay. R2 = 0.1585; P = 0.788. The R and P values
in A and B were determined by two-tailed Spearman correlations. ctr, control;
LOD, limit of detection; ns, not significant.
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of the antibody–pathogen interaction can influence the ability of
the Fc to engage its receptor (DiLillo et al., 2016).
To determine which Fc receptors are responsible for en-
hanced protective activity, we grafted the variable domains of
C104 onto the mouse IgG1 or IgG2a Fc or the mouse IgG1 Fc
variant IgGD265A, which is a null-binding mutant for all mouse Fc
receptors (Clynes et al., 2000). Mouse subclasses display dif-
ferential affinity for the activating (FcRI, III, and IV) and the
inhibitory (FcRIIB) receptors (Nimmerjahn and Ravetch, 2005).
Since activating and inhibitory receptors are coexpressed on
most effector cells, the in vivo activity of an IgG Fc is the result of
the differential affinity of Fc binding to these receptors. Mouse
IgG1 binds preferentially to FcRIIB, an inhibitory receptor, while
IgG2a binds primarily FcRIV receptor, an activating receptor.
FcRIV is expressed on monocytes/macrophages, neutrophils,
and dendritic cells but not on murine natural killer cells
(Bournazos et al., 2017). As expected, the three mouse antibody
variants (i.e., C104-IgG1, IgG2, or D265A) had neutralization
potencies that were not significantly different from each other’s
or that of their human IgG1 counterpart in SARS-CoV-2 S-MA
Table 2. SARS-CoV-2 MA virus lung titers with single hu-mAb prophylaxis
Antibody ID C002 C104 C105 C110 C119 C121-LS C135-LS C144-LS Isotype control
Dose level (mg/kg) 8 8 8 8 8 8 8 8 8
Number of animals 10 10 10 10 9 10 9 10 10
Minimum (PFU/ml) 4.5E+01 4.5E+01 2.5E+03 4.5E+01 1.0E+05 1.5E+02 4.5E+01 4.5E+01 4.5E+05
Maximum (PFU/ml) 7.5E+03 4.5E+01 6.3E+04 6.0E+03 1.5E+06 7.5E+03 3.5E+03 2.0E+03 3.0E+06
Range 7.5E+03 0.0E+00 6.0E+04 6.0E+03 1.4E+06 7.4E+03 3.5E+03 2.0E+03 2.6E+06
Geometric mean (PFU/ml) 9.9E+02 4.5E+01 1.3E+04 2.2E+02 4.9E+05 1.1E+03 3.3E+02 1.5E+02 1.0E+06
Geometric SD factor 8.6 1.0 2.6 6.9 2.5 4.0 4.8 5.0 1.8
Figure 3. The variable requirement of Fc-effector function for SARS-CoV-2 neutralization. (A) Antibody potency curves for WT and GRLR mutant
antibodies. The % neutralization for cell lysates of HT1080muAce2 cells 48 h after infection with SARS-CoV-2 S-MA pseudovirus in the presence of increasing
concentrations of WT (solid lines) or GRLR-modified (dashed lines) mAbs. Data points are shown as closed (WT) or open (GRLR) circles, and corresponding
curve fits are shown as continuous (WT) or dashed (GRLR) lines. Data are mean of duplicates, and one representative experiment is shown. ctr, control. (B) IC90
values for antibodies shown in A. Bars represent mean values of two experiments (shown as open circles). (C) SARS-CoV-2 MA lung titer following antibody
prophylaxis. WT or GRLR antibodies (8 mg/kg) were delivered intraperitoneally 12 h before infection with 105 PFU of SARS-CoV-2 MA. Combined data from two
independent experiments are shown, and all groups are n = 10 mice/group. The line is at the geometric mean, and each symbol represents the titer for a single
animal. Asterisks indicate statistical differences compared with isotype control by Mann-Whitney test (**, P < 0.004; ***, P = 0.0001). (D) Antibody potency
curves for WT and Fc mutant antibodies performed and displayed similarly to those in A. (E) IC90 values for the Fc mutant antibodies shown in D. Bars
represent mean values of two experiments (shown as open circles). (F) SARS-CoV-2 MA lung titer following antibody prophylaxis with chimeric mAb comprised
of the variable domains of C104 grafted onto constant regions of mouse IgG1, IgG2b, and IgGD265A. WT C104– and isotype control antibody–treated groups
were controls. Antibodies (8 mg/kg) were delivered intraperitoneally 12 h before infection with 105 PFU of SARS-CoV-2 MA. One independent experiment is
shown. All groups are n = 5 mice/group. The line is at the geometric mean, and each symbol represents the titer for a single animal. Asterisks indicate statistical
differences compared with isotype control by one-way ANOVA with Dunnett’s multiple comparison test or Mann-Whitney test (*, P = 0.022; ***, P =
0.0001–0.0003; ****, P < 0.0001). LOD, limit of detection; ns, not significant.
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pseudovirus assays in vitro (Fig. 3, D and E; and Table 3).
Whereas mouse C104-IgG2a provided a similar level of protec-
tion as WT human C104 (human IgG1, a human subclass that
engages mouse FcRIV), mouse C104-IgG1 and the C104-IgGD265A
variant were significantly less active (Fig. 3 F and Table 3). We
conclude that activating Fc receptors contributes to optimal
protection against SARS-CoV-2 MA in vivo.
Antibody combinations potently neutralize SARS-CoV-2 in vivo
Combinations of antibodies targeting nonoverlapping epitopes
have the potential to increase antiviral potency and can prevent
the emergence of antibody escape mutations (Hansen et al.,
2020; Weisblum et al., 2020 Preprint). To test whether there
might be a benefit of antibody combinations for in vivo pro-
tection, we tested mixtures of antibodies that target nonover-
lapping epitopes on the RBD (C135-LS/C121-LS and C135-LS/
C144-LS; Robbiani et al., 2020). The antibody mixtures were
tested at combined total doses of 16, or 5.3, or 1.8 mg/kg com-
pared with 8 mg/kg of each antibody alone or 16 mg/kg of iso-
type control. As expected, the isotype control antibody failed to
reduce virus replication (Fig. 4). While 16 mg/kg of C135/C121
provided sterilizing protection (i.e., viral titers below the limit of
detection) from SARS-CoV-2MA replication in all mice tested (n =
15), C135/C144 performed nearly as well with only 1 of 15 mice
tested having a low but measurable virus titer (Fig. 4 and Table 4).
Whereas C135/C144 was sterilizing at 5.3 mg/kg, half of the C135/
C121 mice had low but detectable viral lung titers. Notably, the 1.8-
mg/kg dose of either combination significantly reduced titers
compared with isotype control antibody but was not as effectivel
as 5.3 or 16 mg/kg (Fig. 4 and Table 4). In addition, the antibody
combination of C135/C144 at 5.3 mg/kg improved the levels of
protection achieved from C135 alone at 8 mg/kg (Fig. 4).
To determine whether the C135/C144 antibody combination
is effective against authentic SARS-CoV-2 in vivo, we performed
prophylactic and therapeutic efficacy studies in Syrian ham-
sters. The antibody combination was administered 24 h
before infection (i.e., prophylactic) or 12 h after infection
(i.e., therapeutic). As a negative control, one group received
antibody directed against HIV (10–1074) prophylactically. Viral
loads in the lungs were determined 3 d after infection, the peak
of replication in this model. In hamsters receiving control
Table 3. SARS-CoV-2 MA virus lung titers with single hu-mAb prophylaxis using GRLR Fc mutants and murine Fc region grafts
Antibody ID C002 C002 GRLR C104 C104 GRLR C110 C110 GRLR Isotype control
Dose level (mg/kg) 8 8 8 8 8 8 8
Number of animals 10 10 10 10 10 10 10
Minimum (PFU/ml) 4.5E+01 4.5E+01 4.5E+01 4.5E+01 4.5E+01 6.5E+02 1.0E+05
Maximum (PFU/ml) 7.5E+03 1.1E+04 4.5E+01 3.0E+03 6.0E+03 2.5E+04 1.1E+06
Range 7.5E+03 1.1E+04 0.0E+00 3.0E+03 6.0E+03 2.4E+04 1.0E+06
Geometric mean (PFU/ml) 9.9E+02 1.6E+03 4.5E+01 6.9E+02 2.2E+02 3.4E+03 4.8E+05
Geometric SD factor 8.6 5.9 1.0 3.2 6.9 3.0 1.8
Antibody ID C104 IgG1 C104 IgG2 C104 D265A C004 GRLR C004 Isotype control
Dose level (mg/kg) 8 8 8 8 8 8
Number of animals 5 5 5 10 10 5
Minimum (PFU/ml) 4.5E+01 4.5E+01 1.5E+03 4.5E+01 4.5E+01 1.2E+06
Maximum (PFU/ml) 2.0E+04 2.0E+02 2.5E+04 3.0E+03 4.5E+01 5.5E+06
Range 2.0E+04 1.6E+02 2.4E+04 3.0E+03 0.0E+00 4.3E+06
Geometric mean (PFU/ml) 7.5E+02 6.2E+01 7.4E+03 6.9E+02 4.5E+01 3.4E+06
Geometric SD factor 15.4 1.9 3.8 3.2 1.0 1.8
Figure 4. Antibody combinations increase in vivo potency. SARS-CoV-
2 MA lung titer following antibody prophylaxis with isotype control
(16 mg/kg) or combinations of C135-LS + C121-LS or C135-LS + C144-LSmixed
at a ratio of 1:1 for combined dose levels of 16, 5.3, or 1.8 mg/kg. Antibodies
were delivered intraperitoneally 12 h before infection with 105 PFU of SARS-
CoV-2 MA. Single antibodies C121-LS, C135-LS, or C144-LS were similarly
administered at 8 mg/kg (n = 8/antibody). Combined data from two inde-
pendent experiments are shown. For 16-mg/kg groups, n = 14 or 15 mice, and
all other groups were 9 or 10 mice/group. The line is at the geometric mean,
and each symbol represents the titer for a single animal. Asterisks indicate
statistical differences compared with isotype control by one-way ANOVA with
a Dunnett’s multiple comparison test (****, P < 0.0001) or Kruskal-Wallis test
with a Tukey’s multiple comparison test (*, P = 0.02–0.04; ***, P = 0.0002;
****, P < 0.0001). LOD, limit of detection.
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antibody, high levels of SARS-CoV-2 replication were observed
in the lung tissue (9 × 105 PFU/100 g tissue; Fig. 5). Prophylactic
administration of the C135/C144 antibody combination pre-
vented or significantly diminished SARS–CoV-2 replication at
all antibody doses tested, including 2 mg/kg (Fig. 5). Similarly,
early therapeutic administration of C135/C144 reduced lung
viral loads below the limit of detection at the 40- and 12-mg/kg
dose levels and decreased viral lung loads >10,000-fold with the
lowest dose tested (4 mg/kg; Fig. 5). We conclude that relatively
low doses of C135/C144 are effective in neutralizing SARS-CoV-
2 both prophylactically and therapeutically.
Discussion
To date, there have been >42 million cases and >1 million deaths
attributed to COVID-19 globally, 20% of which have occurred in
the United States (Johns Hopkins University, 2020). In addition
to the many vaccines and drugs now being tested, passive
transfer of potent hu-mAbs holds great promise for COVID-19
prevention and therapy. Neutralizing hu-mAbs targeting SARS-
CoV-2 promote reduction in viral load and prevent infection in
macaques and hamsters (Hansen et al., 2020; Rogers et al., 2020;
Ju et al., 2020). Here, we examined the relationship between
antibody neutralizing potency in in vitro assays and protection
in two small animal models of SARS-CoV-2 infection (Dinnon
et al., 2020). The results suggest that engagement of activating
Fc receptors can enhance the efficacy of anti–SARS-CoV-2 anti-
bodies in vivo. Moreover, some antibody combinations can be
effective for prevention and early therapy for SARS-CoV-2 even
at relatively low doses.
The neutralizing activity of antibodies to SARS-CoV-2 has
primarily been tested in vitro using pseudotype viruses and
microneutralization assays (Schmidt et al., 2020). How these
in vitro results translate to in vivo protective activity had not
been determined. Our results indicate that the relationship be-
tween neutralizing activity against SARS-CoV-2 MA in vitro and
antiviral activity in vivo is not linear. Antibody half-life and
bioavailability are important variables that can account for this
difference. An additional, potentially important factor is the role
of leukocyte Fc receptors on viral clearance and infected cell
killing in vivo (Bournazos et al., 2020). Indeed, Fc receptors play
an important role in viral clearance during HIV-1, Ebola virus,
and influenza virus infections (Lu et al., 2016; Halper-Stromberg
et al., 2014; DiLillo et al., 2014). Our experiments indicate that Fc
receptors also contribute to optimal antibody-mediated protec-
tion against SARS-CoV-2. Among this family of receptors, acti-
vating Fc receptors on macrophages, neutrophils, and dendritic
cells are critical for enhanced antibody protection against SARS-
CoV-2 MA (Mercado et al., 2020). Thus far, the evidence from
both SARS-CoV-2 vaccine and hu-mAb studies does not support
the notion that antibody-dependent enhancement (ADE) of in-
fection driven by Fc-receptor engagement occurs with SARS-
CoV-2 as is observed for a feline CoV (feline infectious perito-
nitis virus; Pedersen, 2014) or flavivirus such as the dengue
virus (Halstead and Katzelnick, 2020; Laczkó et al., 2020). In
addition, exacerbation of dengue virus infection by ADE is
driven by antibody-dependent increases in infection frequency
of antigen-presenting cells (monocytes, macrophages, dendritic
cells, etc.) normally targeted by dengue virus, while the major
cellular targets of SARS-CoV-2 are respiratory epithelial cells
(Wang et al., 2017). Thus, there is currently little evidence to
suggest that passively transferred immunity via hu-mAb ther-
apy will initiate immune pathologies such as ADE.
An additional nonmutually exclusive explanation for the
disparity between the in vivo antiviral activity and the in vitro
Table 4. Comparison of SARS-CoV-2 MA virus lung titers with either single hu-mAb or hu-mAb combination prophylaxis
Antibody ID C121-LS C135-LS C144-LS C135-LS+C121-LS C135-LS+C144-LS Isotype
control
Dose level (mg/kg) 8 8 8 16 5.3 1.8 16 5.3 1.8 16
Number of animals 10 9 10 15 9 10 15 10 10 14
Minimum (PFU/ml) 1.5E+02 4.5E+01 4.5E+01 4.5E+01 4.5E+01 4.5E+01 4.5E+01 4.5E+01 4.5E+01 3.3E+05
Maximum (PFU/ml) 7.5E+03 3.5E+03 2.0E+03 4.5E+01 6.0E+02 4.5E+05 3.0E+02 4.5E+01 1.2E+05 4.5E+06
Range 7.4E+03 3.5E+03 2.0E+03 0.0E+00 5.6E+02 4.5E+05 2.6E+02 0.0E+00 1.1E+05 4.2E+06
Geometric mean (PFU/ml) 1.1E+03 3.3E+02 1.5E+02 4.5E+01 1.2E+02 9.3E+03 5.1E+01 4.5E+01 6.9E+03 1.2E+06
Geometric SD factor 4.0 4.8 5.0 1.0 2.8 21.9 1.6 1.0 18.6 2.4
Figure 5. Prevention and therapy with C135-LS + C144-LS antibody
combination in Syrian hamsters. Hamsters were infected intranasally with
2.6 × 104 PFU SARS-CoV-2, and viral lung titers 3 d after infection were
determined by plaque assay on Vero-E6 cells. Antibodies were administered
either 24 h before (prophylactic) or 12 h after (treatment) infection. The line is
at the geometric mean, and each symbol represents the titer for a single
animal. Dotted line indicates the limit of detection. Asterisks indicate sta-
tistical differences compared with isotype control by one-way ANOVA with a
Dunnett’s multiple comparison test (**, P < 0.01). LOD, limit of detection.
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neutralization results relates to heterogeneity in the way neu-
tralizing antibodies target the SARS-CoV-2 RBD (Barnes et al.,
2020a Preprint; Barnes et al., 2020b). Antibodies can neutralize
by binding to the ACE2 interaction surface, thereby blocking
RBD interaction with its cellular receptor directly or indirectly.
Even among the antibodies that directly block the interaction
between the RBD and ACE2, there is significant heterogeneity in
terms of their angles of approach to binding. Among neutraliz-
ing antibodies that target the RBD, C144 belongs to a particularly
potent class whose mechanism of action involves blocking RBD–
ACE-2 interaction and additionally locking the RBD in a closed
configuration, making it inaccessible to ACE2 (Barnes et al., 2020a
Preprint; Barnes et al., 2020b). C002, C104, and C105 also bind to
the ACE2 interacting surface of the RBD, but they approach the
RBD from different angles and bind by different mechanisms
(Barnes et al., 2020a Preprint; Barnes et al., 2020b). C104 is the
least potent neutralizer of the three antibodies in vitro but the
most effective against SARS-CoV-2 MA in vivo. Among other
factors, the angle of approach of an antibody to the RBD may alter
its in vivo potency by influencing accessibility of the Fc domain to
its receptor on effector cells, as suggested for neutralizing anti-
bodies to influenza (DiLillo et al., 2016).
In vitro experiments with chimeric vesicular stomatitis virus
(VSV)–SARS-CoV-2 viruses indicate that antibodies can select
for escape mutants and that combinations of antibodies target-
ing nonoverlapping sites can prevent the emergence of resistant
variants (Hansen et al., 2020; Weisblum et al., 2020 Preprint).
Antibody combinations also have the potential to act synergis-
tically, but there is little evidence for synergy in vitro (Robbiani
et al., 2020; Liu et al., 2020; Rogers et al., 2020; Zost et al.,
2020b). Nevertheless, we showed that some combinations of
antibodies outperform single antibodies in neutralizing SARS-
CoV-2 MA in mice. Antibody combinations that target non-
overlapping epitopes may be especially promising for clinical
development because they can be dose sparing and also prevent
selection of resistant variants.
In summary, the data support the idea that specific combi-
nations of antibodies with intact Fc-effector function should be
developed for optimal protection and therapy against SARS-CoV-2.
Material and methods
Cells and viruses
Human Ace2-expressing HT1080 cells (HT1080Ace2cl.14) were
described previously (Schmidt et al., 2020). For constitutive
expression of murine Ace2 (muAce2) in HT1080 cells, a cDNA-
encoding muAce2 was inserted into a lentiviral vector CSIB 39 to
the SFFV promoter. HT1080muAce2 cells were generated by
transduction with CSIB-based virus followed by selection with
5 µg/ml blasticidin.
Cells were cultured in DMEM supplemented with 10% FCS at
37°C and 5% CO2. Medium for Ace2-overexpressing cell lines
contained 5 µg/ml blasticidin. All cell lines had tested negative
for contamination with mycoplasma, and parental cell lines
were obtained from the American Type Culture Collection. Re-
combinant SARS-CoV-2 MA virus was generated as described
previously (GenBank accession no. MT844088; Dinnon et al.,
2020). For virus titration by plaque assay, the caudal lobe of
the right lung was homogenized in PBS, and the resulting ho-
mogenate was serial-diluted and inoculated onto confluent
monolayers of Vero E6 cells, followed by agarose overlay. Pla-
ques were visualized with overlay of neutral red dye on day
2 after infection (Dinnon et al., 2020).
Antibody production
All antibodies were produced as previously described (Mouquet
et al., 2011). Briefly, 293-6E cells that were maintained in Free-
style 293 Expression Medium (Thermo Fisher Scientific) were
transiently transfected by using equal amounts of Ig heavy and
light chain expression vectors using branched polyethylenimine
(Sigma). 7 d after transfection, cells were spun down at 4,200 g
for 40 min at 4°C, and supernatants were filtered through a
0.22-µM filter (Millipore). Antibodies were purified from fil-
tered supernatants using Protein G Sepharose 4 Fast Flow (Cy-
tiva). Antibodies were buffer exchanged and concentrated into
PBS using an Amicon Ultra centrifugal filter (Millipore).
SARS-CoV-2/SARS-CoV-2 MA pseudotyped reporter virus
SARS-CoV-2 pseudotyped particles were produced by co-
transfection of pNL4-3ΔEnv-nanoluc and pSARS-CoV-2-MA-
Strunc in 293T cells (Schmidt et al., 2020; Robbiani et al., 2020).
For generation of SARS-CoV-2 MA pseudotyped particles, a
plasmid expressing the mouse-adapted SARS-CoV-2 S (pSARS-
CoV-2-MA-Strunc) was generated by introducing the Q498Y/
P499T mutation into pSARS-CoV2-Strunc and was used for co-
transfection with pNL4-3ΔEnv-nanoluc.
SARS-CoV-2 MA pseudotyped virus neutralization assay
A 40-µg/ml initial dilution of mAbs was fourfold serially diluted
over 11 dilutions. 55 µl of antibody dilutions was incubated with
a 55-µl aliquot of SARS-CoV-2 MA pseudotyped virus (con-
taining ∼103 infectious units) for 1 h at 37°C. 100 µl of the
mixture was subsequently incubated with HT1080muAce2 cells
for 48 h. Consequently, the resulting antibody starting dilution
was 10 µg/ml, and each well received 50 µl virus. Following
incubation, cells were washed with PBS and lysed with Lucif-
erase Cell Culture 5× reagent (Promega), and nanoluc luciferase
activity in cell lysates was measured using the Nano-Glo Lucif-
erase Assay System (Promega). RLUs obtained were normalized
to those derived from cells infected with SARS-CoV-2 MA
pseudovirus in the absence of mAbs (equivalent to 0% neutral-
ization). The half-maximal and 90% ICs (IC50 and IC90) for mAbs
were determined using four-parameter nonlinear regression
(GraphPad Prism). In detail, we applied the least squares re-
gression method without weighting, with top and bottom values
constrained to 0 (% neutralization) and 100 (% neutralization),
respectively, while allowing for a variable HillSlope.
Mouse studies and in vivo infections
All mouse studies were performed at the University of North
Carolina (AnimalWelfare Assurance #A3410-01) using protocols
(19–168, 20–114) approved by the University of North Carolina
Institutional Animal Care and Use Committee. All animal work
was approved by the Institutional Animal Care and Use
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Committee at University of North Carolina at Chapel Hill ac-
cording to guidelines outlined by the Association for the As-
sessment and Accreditation of Laboratory Animal Care and the
US Department of Agriculture. All work was performed with
approved standard operating procedures and safety conditions for
SARS-CoV-2. Our institutional BSL3 facilities are designed to con-
form to the safety requirements recommended by Biosafety in
Microbiological and Biomedical Laboratories, the US Department of
Health and Human Services, the Public Health Service, the Centers
for Disease Control and Prevention, and the National Institutes of
Health. Laboratory safety plans have been submitted, and the fa-
cility has been approved for use by the University of North Carolina
Department of Environmental Health and Safety and the Centers
for Disease Control and Prevention. 12-mo-old female BALB/c mice
(Envigo; #047) were inoculated with the indicated concentration of
antibody intraperitoneally 12 h before infection. For infection, mice
were anesthetized with a mixture of ketamine/xylazine and in-
fected with 105 PFU of SARS-CoV-2 MA in 50 µl PBS intranasally.
Mice were monitored daily for body weight changes. At 2 d after
infection, mice were euthanized, and lung tissue was harvested for
viral titer analysis. Samples were stored at −80°C until homoge-
nized and titered by plaque assay as described above.
Hamster studies and in vivo infections
8-wk-old Syrian hamsters obtained from Envigo were housed
four per cage under ABSL3 containment. Groups of hamsters
were treated with varying doses of a combination of two anti-
bodies to SARS-CoV-2 RBD, an irrelevant (10–1074; anti-HIV)
antibody, or PBS. Antibodies were administered by the intra-
peritoneal route either 24 h before or 12 h after challenge. Virus
challenge was conducted under ketamine-xylazine anesthesia
by intranasal instillation of 100 μl of SARS-CoV-2 that had been
passaged once in Vero and once in Vero E6 cells; the dose de-
termined by back-titration of the inoculum was 2.6e4 PFU. Be-
ginning 2 d before challenge and extending until euthanasia,
hamsters were evaluated clinically and weighed and their tem-
perature recorded once daily. An equal number of hamsters
from each treatment group was euthanized and necropsied 3 d
after challenge. For animals euthanized on day 3, a sample of
∼100mg of right cranial and right caudal lung lobes was excised,
immersed in 0.9 ml of BA1/FBS, and homogenized using a mixer
mill with stainless steel balls. Tissue homogenates were frozen
to −80°C until assay. Virus titrations were performed using a
double-overlay plaque assay on Vero E6 cells in 6-well plates.
Briefly, serial 10-fold dilutions of tissue homogenate samples
were inoculated onto drained monolayers and incubated 45 min,
and 2 ml of a first overlay (0.5% agarose in MEM) without
neutral red was added to each well. 1 d later, a second 2-ml
overlay containing 0.06 mg/ml neutral red was added to each
well, and plaques were counted 1 and 2 d later.
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